TGF-β Pathway Inhibition for Epilepsy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for epilepsy and other neurological disorders, such as traumatic brain injury and neurodegenerative diseases, are inadequate in addressing the underlying mechanisms of epileptogenesis and astrocyte dysfunction, particularly in relation to blood-brain barrier disruption and transforming growth factor-beta (TGF-β) pathway activation.
Innovation Solution
Administering an effective amount of an agent that blocks the TGF-β pathway to reduce seizure incidence and severity, return astrocytes to a resting state, and improve cognitive function, using TGF-β receptor antagonists, inhibitors, and interfering nucleic acids to target downstream elements of the TGF-β pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for epilepsy are used, then seizure control is achieved, but the underlying mechanisms of epileptogenesis and astrocyte dysfunction are not addressed
Solution Approach 1:
The patent changes the therapeutic parameter from general seizure control to specific TGF-β pathway inhibition. By targeting the TGF-β pathway with specific inhibitors (such as TGF-β receptor antagonists or Smad inhibitors), the treatment addresses the underlying molecular mechanisms of epileptogenesis rather than only controlling symptoms, thereby improving both reliability and adaptability.
Solution Approach 2:
The TGF-β pathway acts as an intermediary mechanism between blood-brain barrier disruption and epileptogenesis. By introducing TGF-β pathway inhibitors as intermediary agents, the patent blocks the harmful signaling cascade that connects BBB damage to seizure generation, addressing the underlying mechanism while maintaining seizure control.
2Strength
If blood-brain barrier disruption is allowed to occur, then vascular damage is minimized, but astrocyte dysfunction and epileptogenesis are promoted
Solution Approach 1:
The patent converts the harmful effect of TGF-β pathway activation (which occurs after BBB disruption) into a beneficial treatment target. By identifying TGF-β signaling as the harmful intermediary that causes astrocyte dysfunction and epileptogenesis, the invention uses specific inhibitors to block this pathway, thereby transforming the understanding of the damage mechanism into a therapeutic opportunity.
Solution Approach 2:
The patent applies preliminary action by blocking the TGF-β pathway before it can fully activate and cause astrocyte dysfunction. By administering TGF-β inhibitors at the time of BBB disruption or in the early stages of epileptogenesis, the treatment prevents the harmful downstream effects rather than addressing them after they have fully developed.
3Reliability
If TGF-β pathway is blocked, then astrocyte dysfunction is addressed and seizure incidence is reduced, but the complexity of treatment mechanisms increases
Solution Approach 1:
The patent extracts the TGF-β pathway as a specific, isolatable target within the complex network of neurological disorders. By focusing on this single pathway (using TGF-β receptor antagonists or Smad inhibitors), the treatment simplifies the approach compared to addressing multiple simultaneous mechanisms, thereby reducing treatment complexity while maintaining effective seizure reduction.
Data Source
AI summary
The present invention provides methods of treating epilepsy and other neurological disorders. The methods generally involve administering to an individual in need thereof an effective amount of an agent that blocks a transforming growth factor-beta pathway.